We found a nonsignificant trend toward a worse dPFS for patients interrupting treatment with residual disease (12‐month dPFS rate 42.9%; 95%CI, 18.2%–100%) compared with those who interrupted treatment after achieving RECIST‐defined CR (12‐month dPFS rate 82.4%; 95% CI, 66.1%–100%; log‐rank p = .063; Fig. 1A ).
← all excerpts
Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma.
1
—
—